Skip to main content

Market Overview

Cantor Is Slashing Its MEI Pharma Price Target


In a report published Tuesday, Cantor Fitzgerald analyst Daniel Brims maintained a Buy rating on MEI Pharma, Inc (NASDAQ: MEIP), while reducing the price target from $14 to $7, after reassessing the risk profile of Pracinostat.

Further clinical development in MDS has increased the risk profile of Pracinostat. "We believe the lack of tolerability which resulted in the failure of the phase 2 trial to meet the primary end point of complete response has substantially increased the risk associated with this clinical program (currently 20% risk adjustment from 70% adjustment previously)," Brims said.

"We believe the duration endpoints of overall survival and progression-free survival are better indicators of clinical benefit, and, though these endpoints are not powered for statistical significance, we believe numerically superior results will justify continued development, given a more tolerant dosing regimen," the analyst explained.

Since there are fewer treatment options for AML patients, doctors may have become increasingly tolerant of a higher adverse event profile. There has been a delay in the Phase III front line AML study in order to evaluate optimized dosing regimens, although "this study can proceed as currently designed," Brims commented.

The analyst believes that the single-arm Phase II trial data demonstrates the efficacy of Pracinostat and there could be a continued robust response rate during the Phase III trial.

"Our peak sales expectation of >$375M is based on conservative penetration rates of 15% in front-line MDS, 30% in second-line MDS, and 35% in AML and risk adjustments of 20% in MDS as well as 70% in frontline AML," Brims added.

Latest Ratings for MEIP

May 2020SunTrust Robinson HumphreyInitiates Coverage OnBuy
Feb 2019BTIG ResearchInitiates Coverage OnBuy
Dec 2018H.C. WainwrightInitiates Coverage OnBuy

View More Analyst Ratings for MEIP
View the Latest Analyst Ratings


Related Articles (MEIP)

View Comments and Join the Discussion!

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Reiteration Analyst Ratings

Latest Ratings

GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at